|

ZR2-ICE Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • RenJi Hospital1

Indications

  • Diffuse Large B Cell Lymphoma Refractory1
  • Diffuse Large B-cell Lymphoma Recurrent1
  • Cancer1

Other1 trial

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.